Cas 440125-25-7,{1-[hydroxy-(2-phenyl-[1,3]-dithian-2-yl)-methyl]pentyl}-carbamic acid tert-butyl ester

440125-25-7

Post Buying Request

Basic information

Product Name: {1-[hydroxy-(2-phenyl-[1,3]-dithian-2-yl)-methyl]pentyl}-carbamic acid tert-butyl ester
Synonyms: {1-[hydroxy-(2-phenyl-[1,3]-dithian-2-yl)-methyl]pentyl}-carbamic acid tert-butyl ester
CAS NO:440125-25-7
Molecular Formula:
Molecular Weight: 411.63
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: {1-[hydroxy-(2-phenyl-[1,3]-dithian-2-yl)-methyl]pentyl}-carbamic acid tert-butyl ester(CAS DataBase Reference)
NIST Chemistry Reference: {1-[hydroxy-(2-phenyl-[1,3]-dithian-2-yl)-methyl]pentyl}-carbamic acid tert-butyl ester(440125-25-7)
EPA Substance Registry System: {1-[hydroxy-(2-phenyl-[1,3]-dithian-2-yl)-methyl]pentyl}-carbamic acid tert-butyl ester(440125-25-7)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 440125-25-7(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

440125-25-7 Suppliers

Recommended suppliers

440125-25-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 440125-25-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,0,1,2 and 5 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 440125-25:
(8*4)+(7*4)+(6*0)+(5*1)+(4*2)+(3*5)+(2*2)+(1*5)=97
97 % 10 = 7
So 440125-25-7 is a valid CAS Registry Number.

440125-25-7Upstream product

440125-25-7Downstream Products

440125-25-7Relevant academic research and scientific papers

PEPTIDIC COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

-

Page 70-71, (2010/11/30)

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 440125-25-7